Daily Cosmetic Research Analysis
Analyzed 20 papers and selected 3 impactful papers.
Summary
A multimodal single-cell atlas of human eyelid skin delineates 13 cell types and their regulatory networks, offering a high-value resource for periocular dermatology and cosmetic science. A randomized, multicenter post-marketing study confirms the effectiveness and safety of a hyaluronic acid filler for chin augmentation, while a phospholipid- and cholesterol-free ethosomal retinol formulation improves chemical stability, transdermal delivery, and tolerability in preclinical testing.
Research Themes
- Single-cell multi-omics resources for skin biology
- Evidence-based outcomes for aesthetic injectables
- Advanced transdermal delivery systems for retinoids
Selected Articles
1. A single-cell multi-omics atlas of human eyelid skin.
Using HT-scCAT-seq on 10,065 cells from adult human eyelid skin, the authors define 13 cell types, their molecular signatures, and enriched gene regulatory networks. This integrated atlas links chromatin accessibility with transcriptomes, creating a high-value reference for periocular skin biology and disease.
Impact: Provides a first-of-its-kind integrated single-cell epigenome–transcriptome map of eyelid skin, informing mechanisms relevant to dermatology, oculoplastic surgery, and cosmetic science.
Clinical Implications: While not directly changing practice, this atlas identifies cell-type-specific regulatory programs that may guide future targets for periocular dermatitis, wound healing, aging-related changes, and safety assessment for topical/cosmetic products near the eye.
Key Findings
- HT-scCAT-seq simultaneously profiled chromatin accessibility and transcriptomes in 10,065 cells from adult human eyelid skin.
- Thirteen distinct cell types were defined with detailed molecular signatures.
- Key cell type–enriched gene regulatory networks were identified across the eyelid skin ecosystem.
Methodological Strengths
- Integrated epigenomic and transcriptomic profiling at single-cell resolution (HT-scCAT-seq).
- Multiple adult donors analyzed, increasing generalizability of cell-state definitions.
Limitations
- Cross-sectional dataset with four adult samples limits inference on dynamics (aging, disease).
- Functional validation of predicted regulatory networks was not reported.
Future Directions: Extend to diverse ages, ethnicities, and disease states (e.g., blepharitis, wound healing), and functionally perturb key regulators to validate therapeutic targets.
The skin acts as the first barrier protecting the human body against the external environment. Transcriptional heterogeneity in human skin is widely confirmed, but the regulatory mechanisms remain largely unexplored. In this study, we employed high-throughput single-cell chromatin accessibility and transcriptome sequencing (HT-scCAT-seq), a technique for simultaneous analysis of the transcriptome and epigenome. We used HT-scCAT-seq to analyze 10,065 cell profiles from four adult human eyelid skin and define 13 distinct cell types. In addition, we described detailed molecular signatures and identified key gene regulatory network enriched in each cell type. Our dataset is a valuable resource for further research in human skin biology.
2. Hyaluronic Acid Filler CPM-V ± Lidocaine for Chin Augmentation: A Randomized, Multicenter, Open-Label Post-Market Follow-Up Study.
In a randomized, multicenter, open-label post-marketing study (n=121), hyaluronic acid filler CPM-V with or without lidocaine increased chin volume by a mean of 2.5 mL at 12–16 weeks and improved projection and aesthetic ratings, with mostly mild to moderate, transient adverse events. No new safety signals were detected.
Impact: Provides randomized, objective 3D-imaged evidence for chin augmentation outcomes with a widely used HA filler, informing product selection and patient counseling.
Clinical Implications: Supports the effectiveness and tolerability of CPM-V (with/without lidocaine) for chin augmentation over 12–16 weeks; clinicians can set realistic expectations on volume gain and projection while monitoring common, transient AEs.
Key Findings
- Randomized allocation to CPM-V (n=58) vs CPM-V+ (n=63) with optional 4-week touch-up; primary endpoint assessed by validated 3D facial imaging.
- Mean chin volume increased by 2.5 mL (95% CI 2.1–2.9; p<0.0001) and G–Sn–Pg angle increased by 1.9° at 12/16 weeks.
- High proportions improved ≥1 point on MAS (91.4%), iGAIS (100%), and pGAIS (99.1%); 24.8% reported treatment-related AEs, mostly mild–moderate and transient.
Methodological Strengths
- Randomized, multicenter design with objective 3D volumetric outcomes.
- Predefined primary and secondary endpoints including validated aesthetic scales and patient-reported outcomes.
Limitations
- Open-label design without blinding may introduce expectation bias.
- Follow-up limited to 12–16 weeks; longer-term durability and rare AEs remain unassessed.
Future Directions: Blinded, longer-term comparative trials versus other fillers and inclusion of durability, migration, and late-onset AEs up to 12 months or more.
BACKGROUND: This post-marketing study evaluated the clinical performance and safety of Belotero METHODS: This prospective, open-label, randomized study was carried out in Germany. Participants seeking chin augmentation received treatment with CPM-V (n=58) or CPM-V+ (n=63), with an optional touch-up 4 weeks after. The primary effectiveness endpoint was change in chin volume (mL) from baseline to 12 weeks after the last injection (Week 12 or Week 16 for participants with touch-up treatment), measured by validated 3D facial imaging. Secondary endpoints included the change from baseline in the glabella-subnasale-pogonion (G-Sn-Pg) angle (°), the investigator- and participant-assessed Global Aesthetic Improvement Scales (iGAIS/pGAIS) scores, the investigator-assessed Merz Aesthetics Scale (MAS) for chin projection, and participant satisfaction with treatment evaluated by FACE-Q - Satisfaction with Chin. Safety was assessed through adverse event reporting. RESULTS: From baseline to Week 12/16, chin volume increased by a mean (standard deviation [SD]) of 2.5 (0.2) mL (95% confidence interval 2.1, 2.9; p<0.0001) and mean (SD) G-Sn-Pg angle increased by 1.9° (1.7°). At Week 12/16, almost all participants experienced ≥1 point improvements from baseline in MAS for chin projection (91.4%), iGAIS (100%), and pGAIS (99.1%). The mean (SD) Rasch-transformed score FACE-Q - Satisfaction with Chin was 66.6 (18.7) at Week 12/16. Thirty participants (24.8%) reported treatment-related adverse events; incidence was similar between treatment groups and the majority of events were mild to moderate in intensity and transient in nature. CONCLUSION: CPM-V and CPM-V+ were effective for chin augmentation in aesthetic clinical practice. No new safety concerns were identified.
3. TPGS Modified Phospholipid-free and Cholesterol-free Ethosomes Enhance Chemical Stability and Transdermal Permeation Of Retinol.
A phospholipid- and cholesterol-free ethosomal carrier, TPGS-modified and built from glyceryl monooleate/poloxamer with a PG/DPG co-solvent, stabilized retinol, reduced particle size to ~50 nm at higher alcohol content, enhanced transdermal permeation and retention, and showed no significant irritation in guinea pigs.
Impact: Introduces an innovative, phospholipid-free ethosomal platform improving retinol stability and skin delivery with favorable tolerability—addressing two key limitations of topical retinoids.
Clinical Implications: If translated clinically, this formulation could enable lower-irritation, more stable retinol products with improved bioavailability, potentially reducing discontinuation and optimizing dosing in dermatologic and cosmetic use.
Key Findings
- TPGS-modified, phospholipid-/cholesterol-free ethosomes reduced hydrated particle size from ~100 nm to ~50 nm as PG/DPG concentration increased from 10% to 30%.
- Compared with aqueous retinol solutions, the formulation substantially decreased retinol degradation at room temperature and maintained particle size stability; antioxidants (tocopheryl acetate, Irganox 1010) further improved stability.
- Enhanced transdermal permeation and skin retention of retinol were achieved without significant irritation upon repeated application in guinea pigs.
Methodological Strengths
- Rational formulation engineering with systematic variation of co-solvent concentration and TPGS modification.
- Multi-metric evaluation including particle size, chemical stability with antioxidants, skin permeation/retention, and in vivo irritation assessment.
Limitations
- Preclinical data without human clinical efficacy or long-term safety outcomes.
- Stability and performance under consumer-use conditions (e.g., light/heat exposure, packaging) were not assessed.
Future Directions: Conduct human patch/irritation and pharmacokinetic studies, head-to-head comparisons with standard retinol formulations, and real-world stability testing in final packaging.
Retinol has emerged as a star ingredient in the cosmetics industry owing to its remarkable skincare efficacy. However, its major limitations-high irritation potential and chemical instability-necessitate further improvement. We developed a liposome primarily composed of glyceryl monooleate and poloxamer (F127). By hybridizing this with a binary alcohol system comprising a 1:1 (v/v) mixture of propylene glycol and dipropylene glycol, an ethosome (ES) capable of efficiently encapsulating retinol was obtained. Retinol-loaded ES (Ret-ES) was further modified with D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS@Ret-ES), thereby optimizing particle size distribution and drug loading capacity. Increasing the binary alcohol concentration from 10 to 30% caused TPGS@Ret-ES hydrated particle size to sharply decrease from 100 to 50 nm, without significant changes in drug loading or encapsulation efficiency. Compared with retinol aqueous solutions, TPGS@Ret-ES substantially reduced degradation rates at room temperature while maintaining excellent particle size stability. Additionally, incorporating antioxidants tocopheryl acetate and Irganox 1010 further improved chemical stability. Notably, TPGS@Ret-ES simultaneously enhanced transdermal drug permeation and skin retention, with no significant irritation observed following repeated application to the same skin site in guinea pigs. In conclusion, ES represents a highly promising topical delivery carrier, and TPGS@Ret-ES shows considerable potential as a novel formulation for retinol.